NRX Pharmaceuticals (NRXP) Gains from Investment Securities (2021 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly Gains from Investment Securities came in at -$3.5 million in Q1 2026, down 22.17% year-on-year from -$4.5 million in Q1 2025, and down 1.64% on a QoQ basis from -$3.5 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Gains from Investment Securities (2021 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 6 years of Gains from Investment Securities data on file, last reported at -$3.5 million in Q1 2026.
- On a quarterly basis, Gains from Investment Securities fell 22.17% year-over-year to -$3.5 million in Q1 2026; TTM through Mar 2026 was $6.5 million, a 619.31% increase from a year earlier, with the FY2025 full-year figure at $5.0 million, up 201.75% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at -$3.5 million, down from -$3.5 million in the prior quarter.
- Over the last five years, Gains from Investment Securities for NRXP reached as high as $8.5 million in Q2 2025 and fell as low as -$3.5 million in Q1 2026.
- Historically, Gains from Investment Securities has averaged $122529.4 across 5 years, with a median of -$19000.0 in 2022.
- On a YoY basis, Gains from Investment Securities climbed as much as 47322.22% in 2025 and fell as far as 32277.78% in 2025.
- Year by year, Gains from Investment Securities stood at -$19000.0 in 2022, then jumped by 136.84% to $7000.0 in 2023, then surged by 26057.14% to $1.8 million in 2024, then tumbled by 290.11% to -$3.5 million in 2025, then declined by 1.64% to -$3.5 million in 2026.
- Per Business Quant data, the three most recent Gains from Investment Securities figures were -$3.5 million in Q1 2026, -$3.5 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | NRX Pharmaceuticals | 117.34 Mn | 110.64 Mn | 437,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.54 Mn |
| Mar 31, 2026 | -3.54 Mn |
| Dec 31, 2025 | -3.48 Mn |
| Dec 31, 2025 | -3.48 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | 8.50 Mn |
| Jun 30, 2025 | 8.50 Mn |
| Mar 31, 2025 | -2.90 Mn |
| Mar 31, 2025 | -2.90 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Sep 30, 2024 | -165,000.00 |
| Sep 30, 2024 | -165,000.00 |
| Jun 30, 2024 | -18,000.00 |
| Jun 30, 2024 | -18,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Dec 31, 2023 | 7,000.00 |